|
RTI 1997-2003:
During 1997-2003, Streptococcus pneumoniae, Haemophilus influenzae
and Moraxella catarrhalis isolates were collected from participant
hospital laboratories in Asia: China, Hong Kong, South Korea, Thailand; North
and South America: Argentina, Brazil, Mexico; Europe: Belgium, France,
Germany, Italy, Spain, United Kingdom; South Africa. Only one isolate per
patient was included. Organisms were derived from clinical specimen sources
including sputum, bronchial washings, bronchial alveolar lavage, nasopharynx,
throat, nose, tracheal aspirate, sinus, ear, eye, cerebrospinal fluid and
blood. Following shipment to a central laboratory, all isolates were
sub-cultured and re-identified using standard clinical laboratory methods.
All isolates were tested for susceptibility to amoxicillin-clavulanate,
azithromycin, ceftriaxone, cefuroxime, clarithromycin, clindamycin,
ciprofloxacin, erythromycin, levofloxacin, penicillin,
trimethoprim-sulfamethoxazole and vancomycin using an extended range of
concentrations of each antimicrobial. Antimicrobial susceptibility testing
was performed using NCCLS broth microdilution, and MICs were interpreted according
to the NCCLS recommendations.
|
